Read the latest positive news, breakthroughs, and inspiring stories about rna therapy, curated daily by BrightWire.
A physician with a rare form of ALS became the first person to receive a drug custom-designed for his specific genetic mutation, and a year later he's still working and showing improved symptoms. The breakthrough opens doors for treating thousands of rare diseases with personalized RNA therapies.
A groundbreaking medication reduced severe swelling attacks by up to 96% in patients with a rare genetic disorder, offering hope with just two doses per year. The treatment could transform life for thousands living with unpredictable, painful episodes.
University of Toronto researchers engineered a breakthrough RNA treatment that could tackle thousands of genetic diseases with a single approach. The therapy teaches cells to ignore faulty "stop signals" that prevent life-saving proteins from forming.
Scientists at University College London have developed the first targeted therapy for children with genetic kidney disease, a condition that currently has no treatment and often leads to lifelong dialysis or transplant. The precision RNA treatment delivered directly to tiny kidney filters reduced protein leakage and scarring in early tests.
A world-first inhaled RNA therapy that targets the root cause of lung disease has entered human trials in Australia. The breakthrough could transform treatment for nine million Australians living with chronic lung conditions.
A groundbreaking RNA therapy just succeeded in early trials for a rare muscular dystrophy affecting thousands, and it could become the first treatment that actually modifies the disease's progression. Novartis's del-brax showed clear signs of reducing muscle damage in patients with facioscapulohumeral muscular dystrophy.
Australian researchers discovered an RNA molecule that destroys the most common type of breast cancer while leaving healthy cells untouched. The breakthrough could lead to new treatments for women whose cancer no longer responds to existing drugs.
Scientists prevented a life-threatening brain condition in newborn mice using RNA therapy, reducing cases by 67%. The breakthrough could spare thousands of babies from risky brain surgery each year.
Scientists at Carnegie Mellon University have discovered a breakthrough approach to target the root cause of myotonic dystrophy type 1, the most common form of adult muscular dystrophy. The precision therapy could finally offer hope to patients with a disease that currently has no effective treatment.
Scientists at Carnegie Mellon University have discovered a precise way to target toxic RNA that causes myotonic dystrophy type 1, the most common adult-onset muscular dystrophy affecting 1 in 2,300 people worldwide. The breakthrough could lead to treatments with fewer side effects for this currently incurable disease and other devastating genetic disorders.
